

# 1 **Reduced brain responsiveness to emotional stimuli with** 2 **escitalopram but not psilocybin therapy for depression**

3  
4 Matthew B. Wall<sup>1,2,3</sup>, Lysia Demetriou<sup>1,2,4</sup>, Bruna Giribaldi<sup>5</sup>, Leor Roseman<sup>5</sup>, Natalie Ertl<sup>1,2</sup>,  
5 David Erritzoe<sup>5</sup>, David J. Nutt<sup>5</sup>, Robin L. Carhart-Harris<sup>5,6</sup>.

6  
7 <sup>1</sup>Invicro London, Hammersmith Hospital, UK

8 <sup>2</sup>Faculty of Medicine, Imperial College London, UK

9 <sup>3</sup>Clinical Psychopharmacology Unit, University College London, UK

10 <sup>4</sup>Nuffield Department of Women's and Reproductive Health, University of Oxford

11 <sup>5</sup>Centre for Psychedelic Research, Division of Psychiatry, Department of Brain Sciences,  
12 Faculty of Medicine, Imperial College London

13 <sup>6</sup>Psychedelics Division, Neuroscape, University of California San Francisco, USA.

14

15

16 Corresponding Author:

17 Matthew B. Wall

18 [matt.wall@invicro.co.uk](mailto:matt.wall@invicro.co.uk)

19

20

## 21 **Funding and Disclosures**

22 This trial was funded by a private donation from the Alexander Mosley Charitable Trust,  
23 supplemented by Founders of ICL's Centre for Psychedelic Research (CPR)  
24 (<https://www.imperial.ac.uk/psychedelic-research-centre/funding-partners/>). Infrastructure  
25 support was provided by the NIHR Imperial Biomedical Research Centre and the NIHR  
26 Imperial Clinical Research Facility.

27 Authors MBW, LD, and NE's primary employer is Invicro LLC., a contract research  
28 organization which provides services to the pharmaceutical and biotechnology industries.  
29 RCH is a scientific advisor to Maya Health, Osmind, Beckley Psytech, Usona Institute,  
30 Mindstate, Entheos Labs, and TRYP therapeutics. DJN is a scientific advisor to Awakn Life  
31 Sciences, and Algernon pharmaceuticals, and Psyched Wellness. DE is a scientific advisor to  
32 Mindstate, Aya Biosciences, and Clerkenwell Health.

33

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

34 **Abstract**

35

36 Psilocybin therapy is an emerging intervention for depression that may be at least as  
37 effective as standard first-line treatments i.e., Selective Serotonin Reuptake Inhibitors  
38 (SSRIs). Here we assess neural responses to emotional faces (fear, happy, and neutral) using  
39 Blood Oxygen-Level Dependent (BOLD) functional Magnetic Resonance Imaging (fMRI) in  
40 two groups with major depressive disorder: 1) a ‘psilocybin group’ that received two dosing  
41 sessions with 25mg plus six weeks of daily placebo, and 2) an ‘escitalopram group’ that  
42 received six weeks of the SSRI escitalopram, plus two dosing sessions with an  
43 inactive/placebo dose of 1mg psilocybin. Both groups had an equal amount of psychological  
44 support throughout. An emotional face fMRI paradigm was completed at baseline (pre-  
45 treatment) and at the six-week post-treatment primary endpoint (three weeks following  
46 psilocybin dosing sessions). An analysis examining the interaction between patient group  
47 (psilocybin vs. escitalopram) and time-point (pre- vs. post-treatment) showed a robust  
48 effect in a distributed network of cortical brain regions. Follow-up analyses showed that  
49 post-treatment BOLD responses to emotional faces of all types were significantly reduced in  
50 the escitalopram group, with no change, or even a slight increase, in the psilocybin group.  
51 Specific analyses of the amygdala showed a reduction of response to fear faces in the  
52 escitalopram group, but no effects for the psilocybin group. Despite large improvements in  
53 depressive symptoms in the psilocybin group, psilocybin-therapy had only a minor effect on  
54 brain responsiveness to emotional stimuli. We suggest that reduced emotional  
55 responsiveness may be a biomarker of SSRIs’ antidepressant action that is not shared by  
56 psilocybin-therapy.

## 57 Introduction

58

59 Major Depressive Disorder (MDD) is one of the most prevalent and debilitating psychiatric  
60 disorders <sup>1</sup>. Current treatment guidelines suggest psychotherapy for mild depression, with  
61 pharmacotherapy or a combination of the two treatments recommended for moderate-to-  
62 severe cases <sup>2</sup>. Pharmacotherapy with Selective Serotonin Reuptake Inhibitors (SSRIs) is a  
63 popular option. However, SSRIs are only moderately effective, take four to eight weeks to  
64 show a meaningful therapeutic response, and have acceptability rates (indexed by  
65 treatment discontinuation) comparable with placebo <sup>3</sup>, i.e. around 25-30% <sup>4</sup>.

66

67 A phenomenon commonly referred to as ‘emotional blunting’ (i.e., a restricted range or  
68 intensity of emotional experience) has been associated with SSRI use, with one survey  
69 suggesting a prevalence close to 50% <sup>5</sup>. Diminished libido and sexual functioning with SSRI  
70 treatment <sup>6,7</sup> and a modest impact on symptoms of anhedonia in depression <sup>8</sup> are also  
71 commonly reported. One potential cause of diminished emotional responsiveness via SSRIs  
72 may be increased 5-HT activity on inhibitory postsynaptic 5-HT<sub>1A</sub> receptors in limbic and  
73 paralimbic circuitry implicated in affective and hedonic functioning <sup>9,10</sup>. Specifically,  
74 decreased amygdala responsiveness to emotional stimuli (i.e. a normalization of responses  
75 to negative stimuli) has been found in depressed patients soon after beginning a course of  
76 SSRIs <sup>11,12</sup>, and similar effects have been found in healthy subjects with short-term use of  
77 SSRIs <sup>13,14</sup>. This emotional/amygdala blunting has been hypothesized to be central to their  
78 therapeutic effect <sup>15,16</sup>.

79

80 Novel treatments for major depression are generating a great deal of interest in psychiatry  
81 <sup>17,18</sup>. Ketamine has shown potential as a rapid-acting treatment option <sup>19</sup>, and promising  
82 results are being seen in small clinical trials assessing psilocybin therapy for depression <sup>20–22</sup>  
83 and depressive symptoms <sup>23–25</sup>. Psilocybin is a naturally occurring ‘classic’ psychedelic which  
84 exerts its characteristic subjective effects through direct agonism of the 5-HT<sub>2A</sub> receptor <sup>26</sup>.  
85 Acutely a 25mg dose of psilocybin has profound effects on spontaneous brain function <sup>27</sup>  
86 and longer-term functional brain changes have been reported with this dose of psilocybin in  
87 depressed <sup>28–30</sup> as well as in healthy individuals <sup>31,32</sup>. In clinical use, psilocybin dosing  
88 sessions can be combined with psychological therapy and support, before (‘preparation’  
89 sessions), during the dosing sessions, and after (‘integration’ sessions)<sup>33</sup>.

90

91 Emotional face perception paradigms are widely used in human fMRI studies, and  
92 particularly in depression research <sup>34</sup>. Using this approach in a sample of patients before and  
93 one-day after psilocybin therapy for treatment-resistant depression we previously observed  
94 an increase in BOLD responsiveness to emotional face stimuli in depressed patients<sup>35</sup>, which  
95 may reflect early changes in responses to treatment or ‘afterglow’ phenomena<sup>36</sup>, i.e., a sub-  
96 acute life in mood. Despite being directionally opposite to the BOLD-reducing action of SSRIs  
97 on emotional faces <sup>11,12,37</sup>, this finding was predictive of longer-term treatment response <sup>35</sup>.

98 An extension of this work identified changes in amygdala connectivity that were also  
99 associated with clinical improvements<sup>38</sup>. In contrast to the emotional blunting associated  
100 with SSRIs, a sense of increased emotional connection is often reported with effective  
101 psychedelic therapy<sup>39</sup>. Thus, a differential effect on emotional functioning between SSRIs  
102 and psychedelic therapy could explain their contrasting fMRI findings in emotional  
103 processing paradigms.

104  
105 The aim of the present study was to directly compare the brain effects of the two  
106 treatments for the first time, in a double-blinded, randomized-controlled trial. We chose  
107 escitalopram as an active comparator for psilocybin therapy because of its high  
108 pharmacological selectivity as a 5-HT reuptake inhibitor and good antidepressant  
109 performance; in terms of both tolerability and efficacy<sup>3,40</sup>. Psilocybin therapy was carried  
110 out in a manner that was generally consistent with previous studies. The clinical procedures  
111 are detailed below and the clinical findings are fully reported elsewhere<sup>41</sup>. The specific  
112 emotional facial expression paradigm employed in this study was similar to those used in  
113 previous work, e.g.<sup>11,35</sup>. The main pre-registered hypothesis for this trial was that the two  
114 treatments would have significantly different effects on brain responsiveness to emotional  
115 faces (see trial registration under identifier NCT03429075;  
116 <https://clinicaltrials.gov/ct2/show/NCT03429075>). This is therefore the first report of the  
117 primary study outcome.

118  
119

## 120 **Methods**

121

122 This study was approved by the Brent Research Ethics Committee, with additional approvals  
123 from the UK Medicines & Healthcare products Regulatory Agency, the Health Research  
124 Authority, and Imperial College London. MRI data collection, drug storage, and dispensing  
125 took place at Invicro LLC, Hammersmith Hospital, London. All subjects gave written  
126 informed consent, and the trial was conducted under the principles of Good Clinical  
127 Practice.

128

### 129 *Design*

130 The full clinical study procedure is reported in <sup>41</sup>. This was a phase II, double-blinded,  
131 randomized, controlled experimental medicine trial. MRI scanning was done prior to any  
132 therapeutic intervention (baseline) and six weeks and one day after the first dosing day. For  
133 the psilocybin group, they received 2 x 25mg doses of psilocybin, three weeks apart. The  
134 post-treatment MR scan occurred three weeks after the second 25mg dose. After the first of  
135 the two dosing sessions, patients in the psilocybin group were provided with a bottle of  
136 capsules containing microcrystalline cellulose (i.e. inert placebo capsules) and instructed to  
137 take one per day for the next three weeks and two per day for the final three weeks until  
138 scan visit two, which was the primary endpoint. Subjects in the escitalopram group received  
139 a 1mg dose of psilocybin on each of the two dosing visits (also three weeks apart); 1mg has  
140 negligible subjective effects and therefore served as a control procedure/placebo. These  
141 subjects were provided with encapsulated escitalopram (10mg capsules) and were  
142 instructed to take one capsule (10mg escitalopram) daily for the first three weeks, and two  
143 capsules (20mg) daily for the final three weeks. Scan visit two occurred on the day of the  
144 final capsule ingestion at the approximate time of peak plasma concentration, implying both  
145 steady state and acute presence of escitalopram for the escitalopram group.

146

### 147 *Clinical scales*

148 The primary pre-registered (<https://clinicaltrials.gov/ct2/show/NCT03429075>) clinical  
149 outcome was the Quick Inventory of Depression Score (QIDS-SR16) <sup>42</sup>. Additional measures  
150 used were the Beck Depression Inventory (BDI) <sup>43</sup>, the Warwick-Edinburgh Mental Well-  
151 being Scale (WEMWBS) for assessment of well-being <sup>44</sup>, the Snaith-Hamilton Pleasure Scale  
152 (SHAPS) <sup>45</sup> for assessment of anhedonia, the Laukes Emotional Intensity Scale (LEIS) <sup>6</sup> for  
153 assessment of emotional function, and the PRSexDQ <sup>46</sup> for assessment of changes to sexual  
154 function.

155

### 156 *Participants and Recruitment*

157 For full details of the recruitment and screening procedures see <sup>41</sup>. Participants were  
158 recruited using trial networks, social media, and other sources, via a recruitment website  
159 (<https://www.imperial.ac.uk/psychedelic-research-centre>). Volunteers emailed the  
160 recruitment coordinator, so all recruited participants were self-referred. There followed a

161 multi-step screening process involving telephone and video calls, and in-person sessions  
162 with a trial psychiatrist.

163

164 Inclusion criteria were: a score of at least 17 (indicating moderate-to-severe MDD) on the  
165 HAM-D-17 assessments which were performed on the video call, confirmation of a diagnosis  
166 of depression and a satisfactory medical history (obtained from the patient's general  
167 physician), willingness to withdraw completely from psychiatric medication (at least two  
168 weeks) and psychotherapy (at least three weeks) before starting the trial, age 18-80 years,  
169 and sufficient competence with English. The main exclusion criteria were a history of certain  
170 exclusory mental or physical health conditions (both physician-assessed), pregnancy,  
171 previous courses of escitalopram, and drug or alcohol dependence.

172

173 Thirty patients were randomized to the psilocybin arm of the study, and 29 were  
174 randomized to the escitalopram arm. However, four patients in the escitalopram arm  
175 discontinued treatment due to side effects and were therefore excluded in the present  
176 analyses. A further five subjects in the escitalopram arm did not complete the second MRI  
177 visit because of Covid-19 lockdowns in the UK in March/April 2020. Four subjects in the  
178 psilocybin arm also did not complete their second MRI scanning session also because of  
179 Covid-19 lockdowns. After the end of the trial, it was revealed that one subject in the  
180 psilocybin arm had been using cannabis regularly throughout the trial, so their data was also  
181 excluded. Consequently, there were N=21 subjects available for analysis in the escitalopram  
182 arm of the study, and N=25 in the psilocybin arm. See figure 1 for the full recruitment flow  
183 diagram.

184




Figure 1. Recruitment flow diagram for the study.

185  
186  
187

### 188 *Task and image acquisition*

189 The fMRI task involved stimuli with three facial expressions: fear, happy, and neutral. These  
190 were selected from the Karolinska Directed Emotional Faces set<sup>47</sup> and presented in blocks  
191 of five images of the same type, with each image on-screen for 3s. Rest/baseline blocks  
192 were also included, which displayed a small fixation cross at the center of the screen. There  
193 were eight repeats of each block type presented in a pre-determined pseudo-random order,  
194 and 32 blocks in total (eight each of fear, happy, neutral, and rest/baseline). The total task  
195 time was eight minutes, plus a 10s buffer period at the end of the task to ensure the last  
196 response was fully captured. Two different pseudo-random orders of block presentation  
197 were used, and subjects saw one order on the first visit and a different order on the second  
198 visit. Patients passively viewed the faces.

199

200 Data was acquired using a Siemens TIM Trio 3 Tesla MRI scanner (Siemens, Erlangen),  
201 equipped with a 32-channel phased-array head-coil. Anatomical images were acquired using  
202 the recommended parameters for MPRAGE by the ADNI-GO project<sup>48</sup>: TE = 2.98ms, TR =  
203 2300ms, 160 sagittal slices, 256x256 in-plane FOV, flip angle = 9°, 1mm isotropic voxels.



204 The functional (Echo-Planar-Imaging) acquisition was based on the multiband EPI WIP v012b  
205 provided by the University of Minnesota<sup>49-51</sup> using a multiband acceleration factor of 2, and  
206 a slice acceleration (GRAPPA) factor of 2 (TR=1250ms, TE=30ms, 44 slices, 3mm isotropic  
207 voxels, FOV = 192x192mm, flip angle = 70°, bandwidth = 2232Hz/pixel, 392 volumes  
208 acquired). This was based on sequences previously tested and validated by<sup>52</sup>.

209

#### 210 *Data analysis*

211 Analysis was conducted using FSL version 5<sup>53</sup>. Processing of the anatomical data used the  
212 `fsl_anat` script, which performs a number of processes including inhomogeneity correction  
213 and brain extraction using BET (Brain Extraction Tool). Pre-processing of the functional data  
214 included head-motion correction, smoothing (6 mm), registration to a standard template  
215 (MNI152) using a two-step registration using the subjects' anatomical scans, and high-pass  
216 filtering (0.01 Hz).

217

218 For the first-level analyses, a general linear model contained regressors derived from the  
219 occurrence of the stimuli in three (fear, happy, and neutral face blocks) separate regressors.  
220 These stimulus-related time-series were convolved with a standard Gamma function to  
221 model the hemodynamic response. An extended set of 24 head-motion regressors were also  
222 included as confounds, which included temporal derivatives and quadratic functions derived  
223 from the raw head-motion parameters. Modelling used FSL's FILM (FMRIB's Improved  
224 Linear Model) for pre-whitening and autocorrelation correction. Contrasts were computed  
225 that compared each stimulus condition with the fixation cross baseline condition, as well as  
226 a summary contrast that modelled all stimulus conditions relative to the fixation cross  
227 baseline.

228

229 To visualize treatment effects, mid-level, fixed-effects, within-subjects analyses were used  
230 to generate comparisons between pre- and post-intervention visits for each subject. Group  
231 analyses were random effects (FLAME-1) models, with statistical maps thresholded at  $Z =$   
232  $2.3$ , and  $p < 0.05$  (cluster corrected). Mean analyses including data from all subjects and all  
233 visits were generated to verify the success of the task paradigm in producing an expected  
234 pattern of brain activation, and the general acquisition and analysis procedures (see  
235 supplementary material for results). Between-subjects group-level analyses then used the  
236 results of the mid-level analyses for a comparison between the two treatment groups  
237 (psilocybin vs. escitalopram). These comparisons modelled both the difference between  
238 groups, and the difference between study visits, and therefore test an interaction effect.  
239 Data were extracted from functional clusters/maps in these group-level analyses and  
240 plotted to visualize the precise pattern of effects across the task conditions, visits, and drug  
241 treatment groups. Additionally, group-level analyses of pre- vs. post-treatment effects were  
242 also performed with an anatomical amygdala mask, derived from the Harvard-Oxford sub-  
243 cortical atlas, provided with FSL. The rationale for this analysis was based on previous work  
244 showing that amygdala connectivity and responsiveness to emotional stimuli can be



245 specifically affected by psilocybin therapy<sup>35,38</sup> and that it is also a region of interest in  
246 depression research<sup>10</sup>. Finally, a control analysis was performed that compared the pre-  
247 therapy (baseline) scans of the two treatment groups, to examine any potential baseline  
248 differences between the two groups.

249

250 Additional exploratory analyses were conducted to examine the relationship between  
251 measures of clinical outcomes, and the BOLD activation data, using Pearson's correlations  
252 and moderation analyses to examine the specific relationships between clinical depression  
253 outcomes, BOLD activation data, and a subjective measure of emotional function.

254 **Results**

255

256 *Demographics*

257

258 Demographic and selected clinical (baseline, pre-treatment) information for this sample are  
 259 shown in table 1. There were no significant differences at baseline between the two groups  
 260 on any demographic or clinical measure except for the QIDS-SR-16 score, where the  
 261 escitalopram group were somewhat higher.  
 262

Characteristic	Escitalopram (N=21)	Psilocybin (N=25)	Difference
<b>Demographic</b>			
Age: Mean±SD (range)	38.19±10.9 (22-60)	42.8±11.7(21-64)	$t(44)=-1.06$ , $p = 0.294$
Female sex: no. (%)	6 (30)	9 (36)	$\chi^2(1) = 0.287$ , $p = 0.592$
White race: no. (%)	17 (80)	24 (96)	$\chi^2(1) = 2.67$ , $p = 0.102$
Employment status: no. (%)			
Employed	16 (76)	16 (64)	$\chi^2(2) = 3.55$ , $p = 0.471$
Unemployed	4 (19)	7 (28)	
Student	1 (5)	2 (8)	
University education (%)	15 (71)	19 (76)	$\chi^2(1) = 0.12$ , $p = 0.725$
Weekly alcohol use, UK Units: Mean±SD (range)	8.55±8.69 (0-30)	4.8±5.8 (0-20)	$t(44)=-1.73$ , $p = 0.090$
No previous psilocybin use: no. (%)	15 (71)	17 (68)	$\chi^2(1) = 0.063$ , $p = 0.801$
Discontinued psychiatric medication for trial: no. (%)	8 (40)	10 (40)	$\chi^2(1) = 0.00$ , $p = 1.0$
<b>Clinical</b>			
Duration of illness, years: Mean±SD (range)	15.3±11.4 (1.5-46)	21.3±11.0(3-44)	$t(44)=-1.84$ , $p = 0.08$
Previous psychiatric medications: Mean±SD (range)	1.95±1.63 (0-5)	2.2±1.68 (0-6)	$t(44)=-0.505$ , $p = 0.616$
Previous use of psychotherapy: no. (%)	19 (90)	23 (92)	$\chi^2(1) = 0.033$ , $p = 0.855$
QIDS-SR-16 score at baseline: Mean±SD (range)	16.3±4.4 (6-22)	13.9±3.4 (7-19)	$t(44)=2.128$ , $p = 0.039$
BDI-1A score at baseline: Mean±SD (range)	28.0±6.73 (10-38)	28.7±6.6 (16-41)	$t(44)=0.34$ , $p = 0.735$

263 Table 1. Demographic information and selected baseline clinical scores for the  
 264 sample. Pre-treatment baseline was 7-10 days before dosing day 1. All inferential  
 265 statistics in the third column are non-significant (at an alpha value of  $p < 0.05$ ) except  
 266 the QIDS-SR-16 baseline score.

267

268 *Clinical data*


269

270 The full clinical results from the entire cohort are presented in <sup>41</sup>, however, selected clinical  
271 data from the restricted cohort of  $n = 45$  that completed the MRI scanning sessions, after  
272 exclusions, is presented here (baseline to six week timepoints). For the primary outcome  
273 measure (QIDS SR-16) a mixed-effects analysis with one between-groups factor (treatment)  
274 and one within-subjects factor (time) showed a significant main effect of treatment group  
275 ( $F[1,44] = 11.76, p = 0.0013$ ) and time ( $F[6,251] = 26.36, p < 0.0001$ ), but no significant  
276 interaction (figure 2A). A similar analysis was used for Beck Depression Inventory (BDI)  
277 scores, which also showed significant main effects of time ( $F[3,113] = 55.89, p < 0.0001$ ),  
278 time ( $F[1,44] = 8.73, p = 0.005$ ), and a significant interaction ( $F[3,127] = 6.49, p = 0.0004$ ),  
279 suggesting a significantly greater decrease in BDI scores in the psilocybin group (figure 2B).

280

281 The same analysis model applied to well-being (WEMWBS) data showed a significant main  
282 effect of time ( $F[2,92] = 20.93, p < 0.0001$ ), a significant main effect of treatment ( $F[1,44] =$   
283  $12.11, p = 0.0011$ ) and a significant interaction between the two factors ( $F[3,127] = 4.97, p =$   
284  $0.0027$ ). These results suggest significantly greater improvement in well-being scores in the  
285 psilocybin treatment group (see figure 2C). A two-way ANOVA analysis of scores on the  
286 Snaith Hamilton Anhedonia Pleasure Scale (SHAPS) showed no main effect of treatment  
287 group ( $F[1,44] = 2.13, p = 0.15$ ), but a significant effect of pre- vs. post-treatment ( $F[1,44] =$   
288  $79.89, p < 0.0001$ ), and a significant interaction ( $F[1,44] = 7.34, p = 0.0096$ ), again suggesting  
289 greater improvement in anhedonia in the psilocybin group (figure 2D). The change (pre- vs.  
290 post-treatment) in scores on perceived emotional responsiveness or intensity (LEIS) were  
291 analysed using an unpaired  $t$ -test, and showed a significant difference between the groups  
292 ( $t[44] = 5.27, p < 0.0001$ ), i.e., there was a relative decrease in emotional-intensity in the  
293 escitalopram group and a relative increase in the psilocybin group (figure 2E). Finally,  
294 change scores on the Psychotropic-Related Sexual Dysfunction Questionnaire (PRSexDQ)  
295 were also significantly different between the two treatment groups ( $t[44] = 3.08, p =$   
296  $0.0036$ ) in this restricted cohort (figure 2F).

297



298  
299

300 Figure 2. Selected clinical data from the fMRI sub-sample analyzed here. Error bars  
301 are standard errors. A: Significant interaction between the treatment groups and  
302 time on Beck Depression Inventory (BDI) scores, \*  $p = 0.0002$ . B: Significant main  
303 effect of treatment on the Quick Inventory of Depressive Symptoms (QIDS), \*  $p =$   
304  $0.002$ . C: Significant differences between the treatment groups on the Warwick-  
305 Edinburgh Mental Well-being Scale (WEMWBS), \*  $p = 0.0031$ . D: Significant  
306 differences between the treatment groups on the Snaith Hamilton Anhedonia  
307 Pleasure Scale (SHAPS), \*  $p = 0.014$ . E: Significant differences between the treatment  
308 groups on change (pre- vs. post-treatment) scores on the Laukes Emotional Intensity

309 Scale (LEIS), \*  $p < 0.0001$ ). F: Significant differences between the treatment groups  
310 on the Psychotropic-Related Sexual Dysfunction Questionnaire (PRSexDQ). \*  $p =$   
311 0.0036. Note, higher scores on the PRSexDQ reflect greater sexual *dysfunction*.

312

### 313 *Imaging data*

314

315 Subject head-motion was assessed and no subjects were excluded on this basis. There were  
316 also no significant differences in head-motion between groups or across study visits; see  
317 supplementary material for full details. Results of an analysis modelling the mean task  
318 activation of all subjects from each group and all scan visits showed the predicted pattern of  
319 task effects, with the emotional faces activating a broad pattern of brain regions including  
320 primary and secondary visual cortex, amygdala, thalamus, insula, and superior frontal  
321 regions (see supplementary figure S1). This pattern is entirely consistent with previous work  
322 (e.g. <sup>54</sup>) and therefore validates the experimental and analysis procedures.

323

324 Results from the main analyses of treatment and drug group effects are shown in figure 3.  
325 This is a complex effect that models the interaction between the (within-subject) pre- and  
326 post-treatment factor and the (between-subjects) treatment group factor. The voxel-wise  
327 analyses found a large network of areas in which there was a decreased BOLD response  
328 post-treatment in the escitalopram group, relative to the psilocybin group. Significant  
329 clusters were evident in the dorsolateral pre-frontal cortex, supramarginal gyrus, mid-insula,  
330 and superior temporal lobe.


331

332 Data was extracted from this set of clusters and plotted across all the stimulus conditions  
333 (figure 3, panels B-E). A mixed-model 2 (group) x 2 (visit) x 3 (facial expression) ANOVA  
334 showed a significant main effect of study visit ( $F[1,44] = 5.27, p = 0.027$ ). There were also  
335 significant interactions between the treatment group and visit factors ( $F[1,44] = 10.83, p =$   
336  $0.002$ ), and the visit and facial expression factors ( $F[2,86] = 10.09, p < 0.001$ ).

337

338 Follow-up comparisons revealed that in the escitalopram group there was a significant  
339 reduction in responses on the second visit (six weeks) for all three individual facial  
340 expressions: fear ( $t[20] = 2.82, p = 0.011$ ), happy ( $t[20] = 3.79, p = 0.001$ ), and neutral ( $t[20]$   
341  $= 2.25, p = 0.036$ ). This effect is also significant when collapsing across all facial expressions  
342 ( $t[29] = 3.16, p = 0.005$ ). All these results survive a Bonferroni-corrected  $p$  threshold of  
343 0.0125, except the neutral faces result. In the psilocybin group, similar comparisons showed  
344 a significant increase in responses on the post-therapy visit for the neutral facial expressions  
345 ( $t[24] = -3.17, p = 0.004$ ). This neutral faces result for the psilocybin group survived the  
346 corrected alpha threshold ( $p = 0.0125$ ). There were no other significant effects.

347



348  
349  
350  
351

Figure 3. Results from the main analysis. Panel A shows results of a voxel-wise ( $Z > 2.3$ ,  $p < 0.05$ , corrected for multiple comparisons) analysis of an interaction effect between the two treatment groups and study visit (psilocybin (pre- > post-




352 treatment) > escitalopram (pre- > post-treatment), showing a relatively greater  
353 activation to faces in the post-treatment scan (relative to the pre-treatment baseline  
354 scan) for the psilocybin group, compared with the escitalopram group. Panels B-E  
355 break down this high-level effect and plot ROI data from this total set of clusters for  
356 all task conditions, groups, and study visits. Results show that the effect is driven by  
357 a decrease in response to all face types in the escitalopram group in the post-  
358 treatment visit, with minimal post-treatment change in the psilocybin group. In fact,  
359 for neutral faces there is an increased activation post-treatment with psilocybin. \* =  
360  $p < 0.05$ , see text for exact values.

361  
362 Figure 4 shows the results of the analyses using a bilateral amygdala mask. These analyses  
363 compared pre- vs. post-treatment effects for the various task contrasts within each group  
364 and found a significant activation cluster in the right amygdala for the escitalopram group,  
365 with a smaller cluster in the right amygdala for the psilocybin group, both on the task  
366 contrast of fear > neutral faces (figure 3, panels A and C). There were no other significant  
367 effects on the other task contrasts conducted in these analyses using the amygdala mask.  
368 Extracting and plotting data from the relevant activation clusters (figure 3; panels B and D),  
369 and comparing baseline to post-therapy responses found that there was no change in the  
370 psilocybin group post-treatment, however, there was a reduction in responses in the  
371 escitalopram group, with a significant effect for the fear faces ( $t[20]=2.33$ ,  $p=0.031$ ).  
372 However, this effect does not survive a multiple-comparisons correction for the four tests  
373 conducted here.  
374



375



376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

Figure 4. Results from analyses using an anatomical amygdala mask for the comparison of pre- vs. post-treatment for the task contrast fear > neutral. The escitalopram group showed relatively large and bilateral activation clusters for this contrast (A) whereas the psilocybin group showed a more dorsal and smaller cluster only in the left amygdala (C). ROI data from these clusters revealed a significant reduction in response to fear faces post-treatment in the escitalopram group, with no effects seen in the psilocybin group. \* =  $p < 0.05$ .

Reassuringly, in the control analysis of the pre-treatment (baseline) scans, BOLD activations were not significantly different between the two groups on any task condition or contrast.

#### *Relationships between BOLD and clinical data*

Exploratory analyses were conducted to examine relationships between the ROI data plotted in figure 2 and the selected clinical data presented in figure 1. Correlations were calculated within each patient group comparing the change in clinical scores (i.e., score at baseline, subtracted from the 6-week follow-up) with the change in BOLD activity (visit 1


395 subtracted from visit 2) from the regions identified in figure 2. There were no significant  
396 correlations present in these analyses. Results can be found in the supplementary material.  
397

398 Additional exploratory work used two moderation analyses to test whether the change in  
399 brain activity (average of all faces) could predict the main clinical outcome (change in QIDS  
400 scores from baseline to six weeks), and whether this was moderated by emotional function  
401 (change in score on the LEIS). In the psilocybin group, the LEIS alone was significantly  
402 predictive of QIDS outcomes ( $Z = -2.24, p = 0.025$ ), but brain activity alone was not ( $Z = -$   
403  $0.07, p = 0.944$ ), and neither was the interaction between the predictor and moderator ( $Z = -$   
404  $0.91, p = 0.363$ ). For the escitalopram group, the change in brain activity was predictive of  
405 BDI outcomes ( $Z = 1.97, p = 0.048$ ), and while the LEIS alone was not ( $Z = 0.36, p = 0.721$ );  
406 the interaction (i.e., a moderation of the predictive power of brain activity via LEIS) was  
407 strongly significant ( $Z = 3.14, p = 0.002$ ).


408  
409 In moderation analyses, the interaction term is the most instructive result, and a significant  
410 result denotes that the relationship between the predictor and the dependent variable is  
411 stronger or weaker, given varying levels of the moderator. In this case, since all three  
412 variables are negative (i.e. relative decreases in brain activity, decreases in depression, and  
413 decreases in emotional function) it implies that - in the escitalopram group - the relationship  
414 between brain function and the clinical outcome (QIDS) is stronger when patients have  
415 greater levels of emotional blunting (i.e. lower scores on the LEIS). LEIS scores were  
416 relatively increased in the psilocybin group, meaning that the significant direct effect of the  
417 LEIS on clinical outcome ( $Z = -2.24$ ) implies that a higher level of emotional function post-  
418 psilocybin-therapy relates to a greater post-treatment reduction in depression scores (i.e.  
419 greater clinical effect) after the psilocybin-therapy. These analyses were also repeated with  
420 the BDI as the dependent variable and showed a similar pattern of results; see  
421 supplementary material.

422

### Psilocybin group



### Escitalopram group



423  
424  
425  
426  
427  
428  
429  
430  
431

Figure 5. Results of exploratory moderation analyses examining the effects of the change in brain activity on the primary clinical outcome (QIDS) and its moderation by a measure of emotional function (LEIS). In the psilocybin group (top) emotional function has a significant effect on clinical outcomes, but there is no significant effect of brain activity and no interaction effect. In the escitalopram group (bottom) the change in brain activity has a robust effect on clinical outcome, and emotional function also has a strong moderating effect, supporting mechanistic assumptions about the action of the SSRI. Significant effects are denoted by a green arrow and \*.

## 432 Discussion

433

434 Consistent with our primary hypothesis for this comparative mechanisms trial, we found  
435 significant differences in brain responsiveness to emotional stimuli after escitalopram  
436 compared with psilocybin for depression. The separate examination of treatment effects  
437 revealed that the between-group differences were largely driven by decreases in  
438 responsiveness post-treatment in the escitalopram group. Null, or opposite (i.e., slightly  
439 increased activation) effects were seen in the psilocybin group, depending on the exact face  
440 type i.e., increased activations post-treatment to neutral faces was seen in the whole brain  
441 analysis. Results were generally consistent whether examining whole brain activations or  
442 focusing specifically on the amygdala. Exploratory moderation analyses suggested that  
443 outcomes were better predicted by the change in brain activity, moderated by changes in  
444 emotional function, in the escitalopram group, whereas clinical outcomes were better  
445 predicted by changes in emotional function in the psilocybin group.

446

447 This study's findings lend support to the view that psilocybin-therapy and SSRIs have distinct  
448 therapeutic mechanisms of action<sup>9</sup>. While both drugs act on the 5-HT system, SSRIs  
449 increase synaptic concentrations of 5-HT by blocking its reuptake, whereas psilocybin  
450 (through its main active metabolite, psilocin) acts as a direct agonist on certain 5-HT  
451 receptors, with a key action on the 5-HT<sub>2A</sub> receptor subtype<sup>26,55</sup>. Increased synaptic 5-HT  
452 via SSRIs should affect all available 5-HT receptors but there is some evidence to suggest  
453 that the activation of inhibitory postsynaptic 5-HT<sub>1A</sub> receptors, which are heavily expressed  
454 in limbic regions<sup>56</sup> and implicated in emotional<sup>57</sup> and sexual functioning<sup>58</sup>, play an  
455 important role in the action of SSRIs. The four to six week lag in antidepressant effects with  
456 SSRIs is thought to be due to a gradual down-regulation of inhibitory 5-HT<sub>1A</sub> pre-synaptic  
457 auto-receptors<sup>59</sup>, allowing a slow disinhibition of serotonergic efflux onto postsynaptic  
458 targets. Although speculative, activating inhibitory postsynaptic 5-HT<sub>1A</sub> receptors in limbic  
459 regions may dampen their responsiveness and account for the emotional blunting and loss  
460 of sexual function described by some patients receiving treatment with SSRIs<sup>7</sup>. The  
461 moderation analyses provided here suggest that this reduction in brain responsiveness to  
462 emotion with SSRIs may be an important factor in their therapeutic action.

463

464 The results of the whole-brain between-groups contrast revealed a pattern of reduced  
465 responsiveness under escitalopram in regions including the DLPFC, temporo-parietal  
466 junction (TPJ), supramarginal gyrus, and secondary somatosensory cortex. These are largely  
467 high-level transmodal regions implicated in a broad range of processes, including social-  
468 cognitive functions. They are not necessarily regions most commonly identified in emotional  
469 face perception<sup>54</sup>, however, a recent meta-analysis<sup>60</sup> highlighted a similar set of regions  
470 involved in empathy for physical pain, emotional situations, and emotional faces. A further  
471 recent meta-analysis of the neural effects of antidepressants as assessed by emotional  
472 response paradigms has also identified effects in a wider set of cortical regions than just the

473 amygdala<sup>10</sup>. Although speculative, the relative preservation of responsiveness in these high-  
474 level cortical regions after psilocybin therapy may relate to its positive modulation of socio-  
475 emotional functioning<sup>61</sup>, an assumption that might also align with the greater  
476 responsiveness to neutral faces post psilocybin therapy.

477

478 Psilocybin therapy is emerging as a potential paradigm-shifting<sup>62,63</sup> treatment for depression  
479 and other commonly comorbid disorders<sup>64</sup>; paradigm-shifting because it is arguably the first  
480 truly effective drug-assisted psychotherapy<sup>41</sup>. This may be because psilocybin enhances  
481 affective psychotherapeutic processes in a different way to other compounds that have  
482 been combined with psychotherapy<sup>65</sup> including SSRIs<sup>66</sup>. Psilocybin therapy appears to have  
483 an efficacy at least comparable to established treatments<sup>20,22,41</sup>, with treatment response  
484 rates of approximately 70% in three recent trials in MDD<sup>21,22,67</sup>, and has a favorable side-  
485 effect and patient acceptance profile. The present finding of a robust difference in the  
486 effects of an SSRI and psilocybin therapy on brain responsiveness to emotional stimuli are  
487 consistent with previous assumptions about their differential therapeutic actions<sup>9</sup>, as well as  
488 this trial's pre-registered primary mechanistic hypothesis  
489 (<https://clinicaltrials.gov/ct2/show/NCT03429075>).

490

491 A generalized emotional blunting is often associated with SSRIs<sup>5</sup>, whereas greater  
492 acceptance of emotions and a multi-faceted sense of reconnection<sup>39,68</sup> is commonplace with  
493 psilocybin-therapy. The differing pattern of effects in the exploratory moderation analyses  
494 presented here also support this perspective. In the psilocybin group, the (relatively  
495 increased) emotional function was shown to have a direct positive effect on clinical  
496 outcome, such that higher levels of emotional function were associated with greater  
497 improvements in clinical symptoms. In the escitalopram group however, the effect of  
498 changes in emotional function was a robust moderator of the effect of brain responses on  
499 the clinical outcome, but in an opposite direction. The relationship between brain function  
500 (decreased responsiveness to faces) and clinical effects (decreased symptom severity) was  
501 strongest for those patients who reported the largest muting of the intensity of their  
502 emotions (LEIS). As others have recently noted<sup>9,16</sup> this emotional blunting associated with  
503 SSRIs may be a key factor in their therapeutic efficacy, and the current findings support this  
504 perspective.

505

506 The importance of the 5-HT<sub>2A</sub> receptor for the action of psychedelics is well established<sup>26</sup>,  
507 as demonstrated for example, via a strong and selective affinity-to-potency relationship<sup>69</sup>,  
508 antagonist pre-treatment blocking the psychedelic effects<sup>70</sup>, and most recently, subjective  
509 psychedelic effects correlating with degree of 5-HT<sub>2A</sub> receptor occupation in the human  
510 brain<sup>71</sup>. 5-HT<sub>2A</sub> receptors are highly expressed throughout the human cortex<sup>56,72</sup>, but  
511 particularly in high-level associative/transmodal regions that undergo marked expansion  
512 throughout brain development<sup>73</sup> and have expanded most evolutionarily<sup>74,75</sup>. A growing  
513 body of evidence has linked 5-HT<sub>2A</sub> receptor signaling with increases in a variety of markers

514 of neuroplasticity<sup>76,77</sup>. The most recent model of psychedelic therapy's mechanism of action  
515 emphasizes a role for enhanced 5-HT<sub>2A</sub>-induced cortical plasticity; opening a window for  
516 healthy psychological change, guided by concomitant psychotherapy<sup>64,78</sup>. In contrast to the  
517 effects of SSRIs, suppressed emotional or limbic responsiveness is not a feature of the  
518 psychedelic therapy model. Indeed, acute emotional release during 'the trip'<sup>79</sup> and then  
519 progress towards greater emotional acceptance and 'reconnection'<sup>39</sup> are thought to be  
520 important components of the psychedelic therapy model. Together with the present results,  
521 replicated findings of increased whole brain functional integrity after psilocybin therapy for  
522 depression<sup>30</sup>, as well as increased dynamic flexibility<sup>29</sup>, imply a different antidepressant  
523 action for psilocybin relative to SSRIs.

524  
525 Regarding this study's design, it should be noted that the final post-treatment scan occurred  
526 hours after the final dose for those in the escitalopram group (coinciding with peak plasma  
527 concentration of the drug) but three weeks after the second of two 25mg psilocybin  
528 sessions for the psilocybin group. The smaller changes in post-treatment brain functioning in  
529 the psilocybin group may be due to the duration since dosing and a different result may  
530 have been found had we scanned closer to the last psilocybin dosing session, as we did in  
531 previous work, where we showed a relative increases in amygdala responses one-day post-  
532 dosing<sup>28</sup>. We believe that the present study's design can be justified however, as the  
533 intention was to capture the enduring antidepressant effects of psilocybin-therapy, and  
534 these were robust at the 6-week endpoint (3 weeks after the final psilocybin dosing  
535 session)<sup>41</sup>. Our current findings can be seen as consistent with previous work in which  
536 healthy volunteers received a single-dose of psilocybin and reduced amygdala responses  
537 were observed at a one-week follow-up, with responses returning to baseline after one  
538 month<sup>80</sup>. Interestingly, a distinct metric (whole-brain network modularity applied to  
539 spontaneous brain activity) has been found to reliably index the antidepressant action of  
540 psilocybin-therapy, but not escitalopram<sup>30</sup>. The implication is that (unlike for SSRIs<sup>11</sup>) the  
541 emotional face paradigm may not be an especially sensitive marker of the antidepressant  
542 action of psilocybin-therapy (on this time-scale), whereas other brain indices may be more  
543 sensitive to its specific action.

544  
545 Some previous work has suggested that SSRIs and related antidepressant drugs have a  
546 selective action on the processing of negatively valenced emotional stimuli<sup>12</sup>. We did not  
547 replicate this result in the whole-brain analysis but we did see suggestions of less  
548 suppression of amygdala responses to happy and neutral faces with escitalopram relative to  
549 its effect on fearful faces. However, consistent with observations from previous work<sup>81,82</sup>,  
550 faces of a negative valence evoked the largest amygdala responses in this study (figure 3). In  
551 alignment with statistical principles, one could suggest that a drug's modulatory action  
552 would be greatest in the domain of functioning that is especially sensitive under baseline  
553 conditions, i.e. in this case, the negatively-valenced domain. It seems plausible therefore

554 that this could account for SSRI's apparent biased action on negatively-valenced emotional  
555 stimuli as seen in previous studies <sup>12</sup>.

556

557 In conclusion, consistent with the primary hypothesis for this trial, fMRI analyses revealed a  
558 reduced brain responsiveness to emotional face stimuli after six weeks of daily escitalopram  
559 but not three weeks after the second of two 25mg dosing sessions with psilocybin-therapy  
560 for major depressive disorder. The escitalopram data is consistent with current theories on  
561 the therapeutic action of SSRIs <sup>15</sup> and the comparison with psilocybin-therapy highlights the  
562 different brain actions of these two different treatment modalities.



563 **References**

564

- 565 1. Malhi GS, Mann JJ. Depression. *The Lancet*. 2018;392(10161):2299-2312.  
566 doi:10.1016/S0140-6736(18)31948-2
- 567 2. Davidson JRT. Major Depressive Disorder Treatment Guidelines in America and Europe.  
568 *The Journal of Clinical Psychiatry*. 2010;71(suppl E1). doi:10.4088/jcp.9058se1c.04gry
- 569 3. Cipriani A, Furukawa TA, Salanti G, et al. Comparative Efficacy and Acceptability of 21  
570 Antidepressant Drugs for the Acute Treatment of Adults With Major Depressive  
571 Disorder: A Systematic Review and Network Meta-Analysis. *Focus*. 2018;16(4):420-429.  
572 doi:10.1176/appi.focus.16407
- 573 4. Machado M, Iskedjian M, Ruiz I, Einarson TR. Remission, dropouts, and adverse drug  
574 reaction rates in major depressive disorder: a meta-analysis of head-to-head trials. *Curr*  
575 *Med Res Opin*. 2006;22(9):1825-1837. doi:10.1185/030079906X132415
- 576 5. Goodwin GM, Price J, De Bodinat C, Laredo J. Emotional blunting with antidepressant  
577 treatments: A survey among depressed patients. *Journal of Affective Disorders*.  
578 2017;221(June):31-35. doi:10.1016/j.jad.2017.05.048
- 579 6. Opbroek A, Delgado PL, Laukes C, et al. Emotional blunting associated with SSRI-induced  
580 sexual dysfunction. Do SSRIs inhibit emotional responses? *International Journal of*  
581 *Neuropsychopharmacology*. 2002;5(2):147-151. doi:10.1017/S1461145702002870
- 582 7. Cascade E, Kalali AH, Kennedy SH. Real-world data on SSRI antidepressant side effects.  
583 *Psychiatry*. 2009;6(2):16. Accessed March 26, 2021. [www.iGuard.org](http://www.iGuard.org)
- 584 8. Cao B, Zhu J, Zuckerman H, et al. Pharmacological interventions targeting anhedonia in  
585 patients with major depressive disorder: A systematic review. *Progress in Neuro-*  
586 *Psychopharmacology and Biological Psychiatry*. 2019;92(December 2018):109-117.  
587 doi:10.1016/j.pnpbp.2019.01.002
- 588 9. Carhart-Harris RL, Nutt DJ. Serotonin and brain function: A tale of two receptors. *Journal*  
589 *of Psychopharmacology*. 2017;31(9):1091-1120. doi:10.1177/0269881117725915
- 590 10. Ma Y. Neuropsychological mechanism underlying antidepressant effect: A systematic  
591 meta-analysis. *Molecular Psychiatry*. 2015;20(3):311-319. doi:10.1038/mp.2014.24
- 592 11. Godlewska BR, Norbury R, Selvaraj S, Cowen PJ, Harmer CJ. Short-term SSRI treatment  
593 normalises amygdala hyperactivity in depressed patients. *Psychological Medicine*.  
594 2012;42(12):2609-2617. doi:10.1017/S0033291712000591
- 595 12. Godlewska BR, Browning M, Norbury R, Cowen PJ, Harmer CJ. Early changes in  
596 emotional processing as a marker of clinical response to SSRI treatment in depression.  
597 *Translational Psychiatry*. 2016;6(11):1-7. doi:10.1038/tp.2016.130

- 598 13. Maron E, Wall M, Norbury R, et al. Effect of short-term escitalopram treatment on  
599 neural activation during emotional processing. *Journal of Psychopharmacology*.  
600 2016;30(1):33-39. doi:10.1177/0269881115620462
- 601 14. McCabe C, Mishor Z, Cowen PJ, Harmer CJ. Diminished Neural Processing of Aversive  
602 and Rewarding Stimuli During Selective Serotonin Reuptake Inhibitor Treatment.  
603 *Biological Psychiatry*. 2010;67(5):439-445. doi:10.1016/j.biopsych.2009.11.001
- 604 15. Harmer CJ, Duman RS, Cowen PJ. How do antidepressants work? New perspectives for  
605 refining future treatment approaches. *The Lancet Psychiatry*. 2017;4(5):409-418.  
606 doi:10.1016/S2215-0366(17)30015-9
- 607 16. Langley C, Armand S, Luo Q, et al. Chronic escitalopram in healthy volunteers has  
608 specific effects on reinforcement sensitivity: a double-blind, placebo-controlled semi-  
609 randomised study. *Neuropsychopharmacol*. Published online January 23, 2023:1-7.  
610 doi:10.1038/s41386-022-01523-x
- 611 17. Nutt D, Erritzoe D, Carhart-Harris R. Psychedelic Psychiatry's Brave New World. *Cell*.  
612 2020;181(1):24-28. doi:10.1016/j.cell.2020.03.020
- 613 18. Carhart-Harris RL, Goodwin GM. The Therapeutic Potential of Psychedelic Drugs: Past,  
614 Present, and Future. *Neuropsychopharmacology*. 2017;42(11):2105-2113.  
615 doi:10.1038/npp.2017.84
- 616 19. Krystal JH, Abdallah CG, Sanacora G, Charney DS, Duman RS. Ketamine: A Paradigm Shift  
617 for Depression Research and Treatment. *Neuron*. 2019;101(5):774-778.  
618 doi:10.1016/j.neuron.2019.02.005
- 619 20. Carhart-Harris RL, Bolstridge M, Rucker J, et al. Psilocybin with psychological support for  
620 treatment-resistant depression: an open-label feasibility study. *The Lancet Psychiatry*.  
621 2016;3(7):619-627. doi:10.1016/S2215-0366(16)30065-7
- 622 21. Carhart-Harris R, Giribaldi B, Watts R, et al. Trial of Psilocybin versus Escitalopram for  
623 Depression. *New England Journal of Medicine*. 2021;384(15):1402-1411.  
624 doi:10.1056/nejmoa2032994
- 625 22. Davis AK, Barrett FS, May DG, et al. Effects of Psilocybin-Assisted Therapy on Major  
626 Depressive Disorder: A Randomized Clinical Trial. *JAMA Psychiatry*. Published online  
627 2020:1-9. doi:10.1001/jamapsychiatry.2020.3285
- 628 23. Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and  
629 sustained decreases in depression and anxiety in patients with life-threatening cancer: A  
630 randomized double-blind trial. *Journal of Psychopharmacology*. 2016;30(12):1181-1197.  
631 doi:10.1177/0269881116675513
- 632 24. Ross S, Bossis A, Guss J, et al. Rapid and sustained symptom reduction following  
633 psilocybin treatment for anxiety and depression in patients with life-threatening cancer:  
634 A randomized controlled trial. *Journal of Psychopharmacology*. 2016;30(12):1165-1180.  
635 doi:10.1177/0269881116675512

- 636 25. Grob CS, Danforth AL, Chopra GS, et al. Pilot study of psilocybin treatment for anxiety in  
637 patients with advanced-stage cancer. *Archives of General Psychiatry*. 2011;68(1):71-78.  
638 doi:10.1001/archgenpsychiatry.2010.116
- 639 26. Nichols DE. *Psychedelics*. 2016;(April):264-355.
- 640 27. Carhart-Harris RL, Erritzoe D, Williams T, et al. Neural correlates of the psychedelic state  
641 as determined by fMRI studies with psilocybin. *Proceedings of the National Academy of  
642 Sciences of the United States of America*. 2012;109(6):2138-2143.  
643 doi:10.1073/pnas.1119598109
- 644 28. Carhart-Harris RL, Roseman L, Bolstridge M, et al. Psilocybin for treatment-resistant  
645 depression: fMRI-measured brain mechanisms. *Scientific Reports*. 2017;7(1):13187.  
646 doi:10.1038/s41598-017-13282-7
- 647 29. Doss MK, Považan M, Rosenberg MD, et al. Psilocybin therapy increases cognitive and  
648 neural flexibility in patients with major depressive disorder. *Translational Psychiatry*.  
649 2021;11(1):1-10. doi:10.1038/s41398-021-01706-y
- 650 30. Daws RE, Timmermann C, Giribaldi B, et al. Increased global integration in the brain  
651 after psilocybin therapy for depression. *Nature Medicine*. Published online 2022.  
652 doi:10.1038/s41591-022-01744-z
- 653 31. McCulloch DEW, Madsen MK, Stenbæk DS, et al. Lasting effects of a single psilocybin  
654 dose on resting-state functional connectivity in healthy individuals. *J Psychopharmacol*.  
655 2022;36(1):74-84. doi:10.1177/02698811211026454
- 656 32. Pasquini L, Palhano-Fontes F, Araujo DB. Subacute effects of the psychedelic ayahuasca  
657 on the salience and default mode networks. *J Psychopharmacol*. 2020;34(6):623-635.  
658 doi:10.1177/0269881120909409
- 659 33. Watts R, Luoma JB. The use of the psychological flexibility model to support psychedelic  
660 assisted therapy. *Journal of Contextual Behavioral Science*. 2020;15(April 2019):92-102.  
661 doi:10.1016/j.jcbs.2019.12.004
- 662 34. Groenewold NA, Opmeer EM, de Jonge P, Aleman A, Costafreda SG. Emotional valence  
663 modulates brain functional abnormalities in depression: Evidence from a meta-analysis  
664 of fMRI studies. *Neuroscience & Biobehavioral Reviews*. 2013;37(2):152-163.  
665 doi:10.1016/j.neubiorev.2012.11.015
- 666 35. Roseman L, Demetriou L, Wall MB, Nutt DJ, Carhart-Harris RL. Increased amygdala  
667 responses to emotional faces after psilocybin for treatment-resistant depression.  
668 *Neuropharmacology*. 2018.
- 669 36. Majić T, Schmidt TT, Gallinat J. Peak experiences and the afterglow phenomenon: When  
670 and how do therapeutic effects of hallucinogens depend on psychedelic experiences?  
671 *Journal of Psychopharmacology*. 2015;29(3):241-253. doi:10.1177/0269881114568040

- 672 37. Murphy SE, Norbury R, O'Sullivan U, Cowen PJ, Harmer CJ. Effect of a single dose of  
673 citalopram on amygdala response to emotional faces. *The British journal of psychiatry :  
674 the journal of mental science*. 2009;194(6):535-540. doi:10.1192/bjp.bp.108.056093
- 675 38. Mertens LJ, Wall MB, Roseman L, Demetriou L, Nutt DJ, Carhart-Harris RL. Therapeutic  
676 mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity  
677 during emotional processing after psilocybin for treatment-resistant depression. *Journal  
678 of Psychopharmacology*. Published online 2020:1-14. doi:10.1177/0269881119895520
- 679 39. Watts R, Day C, Krzanowski J, Nutt D, Carhart-Harris R. Patients' Accounts of Increased  
680 "Connectedness" and "Acceptance" After Psilocybin for Treatment-Resistant  
681 Depression. *Journal of Humanistic Psychology*. 2017;57(5):520-564.  
682 doi:10.1177/0022167817709585
- 683 40. Cipriani A, Santilli C, Furukawa TA, et al. Escitalopram versus other antidepressive agents  
684 for depression. *Cochrane Database of Systematic Reviews*. 2009;(2).  
685 doi:10.1002/14651858.CD006532.pub2
- 686 41. Carhart-Harris R, Giribaldi B, Watts R, et al. Trial of Psilocybin versus Escitalopram for  
687 Depression. *New England Journal of Medicine*. 2021;384(15):1402-1411.  
688 doi:10.1056/nejmoa2032994
- 689 42. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-item Quick Inventory of Depressive  
690 Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): A  
691 psychometric evaluation in patients with chronic major depression. *Biological  
692 Psychiatry*. 2003;54(5):573-583. doi:10.1016/S0006-3223(02)01866-8
- 693 43. Beck AT, Steer RA, Carbin MG. Psychometric properties of the Beck Depression  
694 Inventory: Twenty-five years of evaluation. *Clinical Psychology Review*. 1988;8(1):77-  
695 100. doi:10.1016/0272-7358(88)90050-5
- 696 44. Tennant R, Hiller L, Fishwick R, et al. The Warwick-Edinburgh Mental Well-being Scale  
697 (WEMWBS): development and UK validation. *Health and Quality of Life Outcomes*.  
698 2007;5(1):63. doi:10.1186/1477-7525-5-63
- 699 45. Snaith RP, Hamilton M, Morley S, Humayan A, Hargreaves D, Trigwell P. A scale for the  
700 assessment of hedonic tone the Snaith-Hamilton Pleasure Scale. *Br J Psychiatry*.  
701 1995;167(1):99-103. doi:10.1192/bjp.167.1.99
- 702 46. Montejo AL, García M, Espada M, Rico-Villademoros F, Llorca G, Izquierdo JA.  
703 [Psychometric characteristics of the psychotropic-related sexual dysfunction  
704 questionnaire. Spanish work group for the study of psychotropic-related sexual  
705 dysfunctions]. *Actas Esp Psiquiatr*. 2000;28(3):141-150.
- 706 47. Goeleven E, De Raedt R, Leyman L, Verschuere B. The Karolinska Directed Emotional  
707 Faces: A validation study. *Cognition & Emotion*. 2008;22(6):1094-1118.  
708 doi:10.1080/02699930701626582

- 709 48. Jack CR, Bernstein MA, Fox NC, et al. The Alzheimer's Disease Neuroimaging Initiative  
710 (ADNI): MRI methods. *Journal of Magnetic Resonance Imaging*. 2008;27(4):685-691.  
711 doi:10.1002/jmri.21049
- 712 49. Cauley SF, Polimeni JR, Bhat H, Wald LL, Setsompop K. Interslice leakage artifact  
713 reduction technique for simultaneous multislice acquisitions. *Magnetic Resonance in*  
714 *Medicine*. 2014;72(1):93-102. doi:10.1002/mrm.24898
- 715 50. Setsompop K, Gagoski BA, Polimeni JR, Witzel T, Wedeen VJ, Wald LL. Blipped-controlled  
716 aliasing in parallel imaging for simultaneous multislice echo planar imaging with reduced  
717 g-factor penalty. *Magnetic Resonance in Medicine*. 2012;67(5):1210-1224.  
718 doi:10.1002/mrm.23097
- 719 51. Xu J, Moeller S, Auerbach EJ, et al. Evaluation of slice accelerations using multiband echo  
720 planar imaging at 3T. *NeuroImage*. 2013;83:991-1001.  
721 doi:10.1016/j.neuroimage.2013.07.055
- 722 52. Demetriou L, Kowalczyk OS, Tyson G, Bello T, Newbould RD, Wall MB. A comprehensive  
723 evaluation of increasing temporal resolution with multiband-accelerated sequences and  
724 their effects on statistical outcome measures in fMRI. *NeuroImage*. 2018;176:404-416.
- 725 53. Smith SM, Jenkinson M, Woolrich MW, et al. Advances in functional and structural MR  
726 image analysis and implementation as FSL. *Neuroimage*. 2004;23:S208-S219.
- 727 54. Fusar-Poli P, Placentino A, Carletti F, et al. Functional atlas of emotional faces  
728 processing: a voxel-based meta-analysis of 105 functional magnetic resonance imaging  
729 studies. *Journal of psychiatry & neuroscience : JPN*. 2009;34(6):418-432.
- 730 55. McClure-Begley TD, Roth BL. The promises and perils of psychedelic pharmacology for  
731 psychiatry. *Nature reviews Drug discovery*. Published online 2022. doi:10.1038/s41573-  
732 022-00421-7
- 733 56. Beliveau V, Ganz M, Feng XL, et al. A High-Resolution In Vivo Atlas of the Human Brain's  
734 Serotonin System. Published online 2017. doi:10.1523/JNEUROSCI.2830-16.2016
- 735 57. Phan KL, Wager T, Taylor SF, Liberzon I. Functional neuroanatomy of emotion: a meta-  
736 analysis of emotion activation studies in PET and fMRI. *NeuroImage*. 2002;16(2):331-  
737 348. doi:10.1006/nimg.2002.1087
- 738 58. Comninos AN, Wall MB, Demetriou L, et al. Kisspeptin modulates sexual and emotional  
739 brain processing in humans. *Journal of Clinical Investigation*. 2017;127(2):709-719.
- 740 59. Celada P, Puig MV, Amargós-Bosch M, Adell A, Artigas F. The therapeutic role of 5-HT1A  
741 and 5-HT2A receptors in depression. In: *Journal of Psychiatry and Neuroscience*. Vol 29.  
742 Canadian Medical Association; 2004:252-265. Accessed March 29, 2021.  
743 /pmc/articles/PMC446220/
- 744 60. Ding R, Ren J, Li S, Zhu X, Zhang K, Luo W. Domain-general and domain-preferential  
745 neural correlates underlying empathy towards physical pain, emotional situation and



- 746 emotional faces: An ALE meta-analysis. *Neuropsychologia*. 2020;137:107286.  
747 doi:10.1016/j.neuropsychologia.2019.107286
- 748 61. Preller KH, Pokorny T, Hock A, et al. Effects of serotonin 2A/1A receptor stimulation on  
749 social exclusion processing. *Proceedings of the National Academy of Sciences of the*  
750 *United States of America*. 2016;113(18):5119-5124. doi:10.1073/pnas.1524187113
- 751 62. Schenberg EE. Psychedelic-assisted psychotherapy: A paradigm shift in psychiatric  
752 research and development. *Frontiers in Pharmacology*. 2018;9(JUL):1-11.  
753 doi:10.3389/fphar.2018.00733
- 754 63. Carhart-Harris RL. Translational Challenges in Psychedelic Medicine. *N Engl J Med*.  
755 2023;388(5):476-477. doi:10.1056/NEJMcibr2213109
- 756 64. Carhart-Harris RL, Chandaria S, Erritzoe DE, et al. Canalization and plasticity in  
757 psychopathology. *Neuropharmacology*. 2023;226:109398.  
758 doi:10.1016/j.neuropharm.2022.109398
- 759 65. G. Hofmann S, T. Sawyer A, Asnaani A. D-Cycloserine as an Augmentation Strategy for  
760 Cognitive Behavioral Therapy for Anxiety Disorders: An Update. *Current Pharmaceutical*  
761 *Design*. 2012;18(35):5659-5662. doi:10.2174/138161212803530916
- 762 66. March JS. Fluoxetine, cognitive-behavioral therapy, and their combination for  
763 adolescents with depression: Treatment for Adolescents with Depression Study (TADS)  
764 randomized controlled trial. *Journal of the American Medical Association*.  
765 2004;292(7):807-820. doi:10.1001/jama.292.7.807
- 766 67. Slosower J, Skosnik PD, Safi-Aghdam H, et al. Psilocybin-assisted therapy for major  
767 depressive disorder: An exploratory placebo-controlled, fixed-order trial. *J*  
768 *Psychopharmacol*. Published online March 20, 2023:2698811231154852.  
769 doi:10.1177/02698811231154852
- 770 68. Watts R, Kettner H, Geerts D, et al. The Watts Connectedness Scale: a new scale for  
771 measuring a sense of connectedness to self, others, and world. *Psychopharmacology*.  
772 Published online August 8, 2022. doi:10.1007/s00213-022-06187-5
- 773 69. Glennon RA, Titeler M, McKenney JD. Evidence for 5-HT<sub>2</sub> involvement in the mechanism  
774 of action of hallucinogenic agents. *Life Sciences*. 1984;35(25):2505-2511.  
775 doi:10.1016/0024-3205(84)90436-3
- 776 70. Vollenweider FX, Vollenweider-Scherpenhuyzen MFI, Bäbler A, Vogel H, Hell D.  
777 Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist  
778 action. *NeuroReport*. 1998;9(17):3897-3902. doi:10.1097/00001756-199812010-00024
- 779 71. Madsen MK, Fisher PM, Burmester D, et al. Psychedelic effects of psilocybin correlate  
780 with serotonin 2 A receptor occupancy and plasma psilocin levels.  
781 *Neuropsychopharmacology*. Published online 2019. doi:10.1038/s41386-019-0324-9

- 782 72. Erritzoe D, Ashok AH, Searle GE, et al. Serotonin release measured in the human brain: a  
783 PET study with [<sup>11</sup>C]CIMBI-36 and d-amphetamine challenge.  
784 *Neuropsychopharmacology*. 2020;45(5):804-810. doi:10.1038/s41386-019-0567-5
- 785 73. Hill J, Inder T, Neil J, Dierker D, Harwell J, Van Essen D. Similar patterns of cortical  
786 expansion during human development and evolution. *Proceedings of the National*  
787 *Academy of Sciences of the United States of America*. 2010;107(29):13135-13140.  
788 doi:10.1073/pnas.1001229107
- 789 74. Rilling JK. Comparative primate neuroimaging: Insights into human brain evolution.  
790 *Trends in Cognitive Sciences*. 2014;18(1):46-55. doi:10.1016/j.tics.2013.09.013
- 791 75. Van Essen DC, Dierker DL. Surface-based and probabilistic atlases of primate cerebral  
792 cortex. *Neuron*. 2007;56(2):209-225. doi:10.1016/j.neuron.2007.10.015
- 793 76. Ly C, Greb AC, Cameron LP, et al. Psychedelics Promote Structural and Functional Neural  
794 Plasticity. *Cell Reports*. 2018;23(11):3170-3182. doi:10.1016/j.celrep.2018.05.022
- 795 77. Vaidya VA, Marek GJ, Aghajanian GK, Duman RS. 5-HT(2A) receptor-mediated regulation  
796 of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex.  
797 *Journal of Neuroscience*. 1997;17(8):2785-2795. doi:10.1523/jneurosci.17-08-  
798 02785.1997
- 799 78. Carhart-Harris RL. How do psychedelics work? *Current opinion in psychiatry*.  
800 2019;32(1):16-21. doi:10.1097/YCO.0000000000000467
- 801 79. Roseman L, Haijen E, Idialu-Ikato K, Kaelen M, Watts R, Carhart-Harris R. Emotional  
802 breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory.  
803 *Journal of Psychopharmacology*. 2019;33(9):1076-1087.  
804 doi:10.1177/0269881119855974
- 805 80. Barrett FS, Doss MK, Sepeda ND, Pekar JJ, Griffiths RR. Emotions and brain function are  
806 altered up to one month after a single high dose of psilocybin. *Scientific Reports*.  
807 2020;10(1):1-14. doi:10.1038/s41598-020-59282-y
- 808 81. Zald DH. The human amygdala and the emotional evaluation of sensory stimuli. *Brain*  
809 *research Brain research reviews*. 2003;41(1):88-123.
- 810 82. Todorov A. The role of the amygdala in face perception and evaluation. *Motiv Emot*.  
811 2012;36(1):16-26. doi:10.1007/s11031-011-9238-5
- 812



## 813 **Supplementary material**

814

### 815 **Head movement**

816

817 Overall head-motion characteristics for all subjects were excellent. Assessment of subject  
818 head-motion during the scans was performed using the displacement time-series produced  
819 during preprocessing of the functional data. These were collated, and means were  
820 calculated across the time-series and across the six (three translations, three rotations)  
821 displacement parameters. Maximum displacement values were also assessed.

822

823 Only one subject showed a maximum displacement value greater than one voxel dimension  
824 (3mm) on a single parameter, for one study visit. Inspection of this subject's time series  
825 showed a single large (~3mm) shift in position part-way through the scan. This subject's  
826 mean displacement (0.088mm) was less than 0.1mm, and was comparable to other subjects  
827 in the sample. It was therefore judged to be acceptable, and the subject was included in the  
828 analyses. Mean displacement across all subjects, scan sessions, and parameters was -  
829 0.00058mm (SD = 0.027mm).

830

831 A 2 (treatment group) by 2 (study visit) mixed-model ANOVA was conducted to examine any  
832 systematic differences in head-motion across these factors. There was no main effect of  
833 treatment group ( $F[1,44] = 1.84, p = 0.182$ ) and no main effect of study visit ( $F[1,44] = 0.11,$   
834  $p = 0.740$ ). There was also no interaction effect ( $F[1,44] = 0.077, p = 0.782$ ).


835

836

837

838 **Group-level task results**

839



840

841 Figure S1. Results from the validation analyses of mean task effects in each group.

842

843

844 **Correlation results**

845

Correlation of BOLD* data with:	Pearson's r	p value
<b>Psilocybin group (N=25)</b>		
BDI change (baseline to six weeks)	0.132	0.529
WEMWBS change (baseline to 6 weeks)	-0.001	0.997
PRSEXDQ	-0.041	0.846
LEIS change (baseline to 6 weeks)	-0.07	0.762
SHAPS change (baseline to 6 weeks)	-0.001	0.998
QIDS change (baseline to 6 weeks)	0.084	0.718
<b>Escitalopram group (N=21)</b>		
BDI change (baseline to six weeks)	0.075	0.748
WEMWBS change (baseline to 6 weeks)	-0.001	0.997
PRSEXDQ	-0.077	0.741
LEIS change (baseline to 6 weeks)	-0.022	0.927
SHAPS change (baseline to 6 weeks)	0.037	0.878
QIDS change (baseline to 6 weeks)	0.187	0.43

846 \*All faces vs. baseline contrast, pre-treatment vs. post-treatment

847

848 Table S1. Correlation analyses between a summary measure of brain activity and key clinical  
849 measures. All analyses showed non-significant/null results.

850

851

852

853 **Moderation Analyses with BDI as the dependent variable**

854

855 The moderation analyses were repeated with BDI change scores (baseline to six-week  
856 follow-up) as the dependent variable. For the psilocybin group, this produced the same  
857 pattern of results as the analysis with QIDS scores in the main text. There was a significant ( $Z$   
858 = -3.02,  $p = 0.003$ ) effect of the LEIS measure on BDI scores, but no effect of brain activity ( $Z$   
859 = -0.29,  $p = 0.774$ ) and no interaction effect ( $Z = 1.32$ ,  $p = 0.187$ ). In the escitalopram group  
860 there were no main effects of either brain activity ( $Z = 1.49$ ,  $p = 0.137$ ) or LEIS ( $Z = -0.59$ ,  $p =$   
861 0.551) on BDI change scores, but a significant interaction effect ( $Z = 2.38$ ,  $p = 0.018$ ).